Recurrent Plasma Cell Myeloma
Conditions
Brief summary
This phase II trial studies how well pembrolizumab works when given together with ixazomib citrate and dexamethasone in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.
Detailed description
PRIMARY OBJECTIVE: I. To determine the overall response rate (\>= partial response \[PR\]) of pembrolizumab in combination with standard doses of ixazomib citrate (ixazomib) and dexamethasone, in patients with relapsed symptomatic multiple myeloma (MM). SECONDARY OBJECTIVES: I. To determine the \>= very good partial response (VGPR) and complete response (CR) rate of pembrolizumab added to standard doses of ixazomib and dexamethasone in relapsed myeloma. II. To determine the progression free survival and overall survival among patients with relapsed MM following treatment with the combination of pembrolizumab, ixazomib and dexamethasone. III. To determine the toxicities associated with pembrolizumab added to standard doses of ixazomib and dexamethasone in patients with relapsed MM. CORRELATIVE RESEARCH: I. PDL-1 expression on myeloma cells and non-tumor cell compartments from the bone marrow will be assessed at baseline. II. Measures of T-cell activation/exhaustion will be assessed at baseline and after cycle 1 and cycle 3. III. Natural killer (NK) cell function and numbers will be evaluated at baseline and after cycle 1 and cycle 3. OUTLINE: Patients receive ixazomib citrate orally (PO) on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab intravenously (IV) over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months until progressive disease, and then every 6 months for up to 2 years.
Interventions
DRUGDexamethasone
Given PO
DRUGIxazomib Citrate
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPembrolizumab
Given IV
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of relapsed, symptomatic multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma * Age \>= 18 years * Calculated creatinine clearance (using Cockcroft-Gault equation below) \>= 30 mL/min (obtained =\< 14 days prior to registration) * Absolute neutrophil count (ANC) \>= 1000/mm\^3 (obtained =\< 14 days prior to registration) * Platelet count \>= 75000/mm\^3; Note: Platelet transfusion is not allowed =\< 3 days prior to registration (obtained =\< 14 days prior to registration) * Hemoglobin \>= 8.0 g/dL (obtained =\< 14 days prior to registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (obtained =\< 14 days prior to registration) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN (obtained =\< 14 days prior to registration) * Must have relapsed or refractory disease after treatments including three therapies: proteasome inhibitors, immunomodulatory imide drugs (IMiDs), and anti-CD38 antibody * Measurable disease of multiple myeloma as defined by at least ONE of the following: * Serum monoclonal protein \>= 1.0 g/dL * \>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis * Serum immunoglobulin free light chain \>= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, or 1 * Provide informed written consent * Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only * Willing to follow strict birth control measures; * Female patients: If they are of childbearing potential, agree to one of the following: * Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 120 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Male patients: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: * Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR * Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) * Willing to provide bone marrow and blood samples for planned research
Exclusion criteria
* Myeloma disease that is refractory to ixazomib treatment * Has a known additional malignancy that is progressing or requires active treatment; exceptions include early stage cancers (carcinoma in situ or stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease * Other concurrent chemotherapy, or any ancillary therapy considered investigational =\< 14 days prior to study registration; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment * Peripheral neuropathy \>= grade 3 on clinical examination or grade 2 with pain during the screening period * Major surgery =\< 14 days prior to study registration * Radiotherapy =\< 14 days prior to registration; NOTE: If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of study drugs * Participation in any other clinical trials with other investigational agents not included in this trial =\< 21 days prior to registration * Has active autoimmune disease that has required systemic treatment =\< 2 years prior to study registration (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); * NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis * Has a known history of interstitial lung disease * Has an active infection requiring systemic therapy * Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent * Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) * Has known active hepatitis B (e.g., hepatitis B surface antigen \[HBsAg\] reactive) or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) * Has a known history of active TB (Bacillus tuberculosis) * Has received a live vaccine =\< 30 days prior to study registration * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Allogeneic hematopoietic stem cell transplant * Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort =\< 14 days prior to registration * Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Percentage | Up to 9 months | Defined as a partial response or better noted as the objective status on two consecutive evaluations. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone | Up to 2 years | Will be estimated by the number of patients who achieve a CR or sCR at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated. |
| Survival Time | Up to 2 years | The distribution of survival time will be estimated using the method of Kaplan-Meier. |
| Progression-free Survival | Up to 2 years | The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. |
| Incidence of Adverse Events | Up to 9 months | Graded according National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. |
| >= Very Good Partial Response (VGPR) Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone | Up to 9 months | Will be estimated by the number of patients who achieve a VGPR, complete response (CR), or stringent complete response (sCR) at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Natural Killer Cell Function and Numbers | Baseline up to Cycle 3 (84 days - each Cycle is 28 days) | Will be summarized descriptively by median, min, max, and interquartile range at each time point. Patterns over time will be summarized by absolute difference or relative change. Changes across time will be assessed using paired analyses, including Wilcoxon signed rank tests. Jitplots will be used to visually examine differences between groups for continuous factors. |
| Markers of T-cell Activation and Exhaustion | Baseline up to Cycle 3 (84 days - each Cycle is 28 days) | Will be summarized descriptively by median, min, max, and interquartile range at each time point. Patterns over time will be summarized by absolute difference or relative change. Changes across time will be assessed using paired analyses, including Wilcoxon signed rank tests. Jitplots will be used to visually examine differences between groups for continuous factors. |
| PDL-1 Expression on Myeloma Cells and Non-tumor Cell Compartments From the Bone Marrow | Baseline | Each measure will be summarized descriptively by median, minimum (min), maximum (max) and interquartile range. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity. | 13 |
| Total | 13 |
Baseline characteristics
| Characteristic | Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) |
|---|---|
| Age, Continuous | 67 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 13 Participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 6 / 13 |
| other Total, other adverse events | 12 / 13 |
| serious Total, serious adverse events | 1 / 13 |
Outcome results
Primary
Overall Response Percentage
Defined as a partial response or better noted as the objective status on two consecutive evaluations. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
Time frame: Up to 9 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | Overall Response Percentage | 0.077 percentage of responders |
Secondary
Complete Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone
Will be estimated by the number of patients who achieve a CR or sCR at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated.
Time frame: Up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | Complete Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone | 0 percentage of responders |
Secondary
Incidence of Adverse Events
Graded according National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
Time frame: Up to 9 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | Incidence of Adverse Events | 13 Participants |
Secondary
Progression-free Survival
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | Progression-free Survival | 1.6 Months |
Secondary
Survival Time
The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | Survival Time | 9 Months |
Secondary
>= Very Good Partial Response (VGPR) Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone
Will be estimated by the number of patients who achieve a VGPR, complete response (CR), or stringent complete response (sCR) at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated.
Time frame: Up to 9 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Ixazomib Citrate, Pembrolizumab, and Dexamethasone) | >= Very Good Partial Response (VGPR) Response Percentage With Pembrolizumab Added to Ixazomib Citrate and Dexamethasone | 0 percentage of responders |
Other Pre-specified
Markers of T-cell Activation and Exhaustion
Will be summarized descriptively by median, min, max, and interquartile range at each time point. Patterns over time will be summarized by absolute difference or relative change. Changes across time will be assessed using paired analyses, including Wilcoxon signed rank tests. Jitplots will be used to visually examine differences between groups for continuous factors.
Time frame: Baseline up to Cycle 3 (84 days - each Cycle is 28 days)
Other Pre-specified
Natural Killer Cell Function and Numbers
Will be summarized descriptively by median, min, max, and interquartile range at each time point. Patterns over time will be summarized by absolute difference or relative change. Changes across time will be assessed using paired analyses, including Wilcoxon signed rank tests. Jitplots will be used to visually examine differences between groups for continuous factors.
Time frame: Baseline up to Cycle 3 (84 days - each Cycle is 28 days)
Other Pre-specified
PDL-1 Expression on Myeloma Cells and Non-tumor Cell Compartments From the Bone Marrow
Each measure will be summarized descriptively by median, minimum (min), maximum (max) and interquartile range.
Time frame: Baseline